NCCN Guidelines Updates: Management of Metastatic Kidney Cancer

Author:
Eric Jonasch
Search for other papers by Eric Jonasch in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 17: Issue 5.5
Online Publication Date:
May 2019
DOI:
https://doi.org/10.6004/jnccn.2019.5008
Restricted access

The NCCN Guidelines for Kidney Cancer have undergone a major shift in the risk categorization used for designating “preferred” and “other recommended” or “useful under certain circumstances” first-line treatments. In the most recent version of the guidelines, “favorable risk” is now its own risk category and “intermediate risk” and “poor risk” are combined into one category. The treatment recommendations for clear cell renal cell carcinoma are continually revised and more new options are anticipated based on encouraging results from pivotal trials. In his presentation at the NCCN 2019 Annual Conference, Dr. Jonasch described these promising findings.

Correspondence: Eric Jonasch, MD, Department of Genitourinary Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1374, Houston, TX 77030. Email: ejonasch@mdanderson.org
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Eng J Med 2018;378:1277–1290.

  • 2.

    Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 2016;375:2246–2254.

  • 3.

    Mejean A, Ravaud A, Thezenas D, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 2018;379:417–427.

  • 4.

    Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Eng J Med 2019;380:1116–1127.

  • 5.

    Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Eng J Med 2019;380:1103–1115.

  • 6.

    McDermott DF, Lee JL, Ziobro M, et al. First-line pembrolizumab monotherapy for advanced non-clear cell renal cell carcinoma: results from KEYNOTE-427 cohort B [abstract]. J Clin Oncol 2019;37(Suppl):Abstract 546.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2019 by the National Comprehensive Cancer Network 2019
Page Numbers:
3
Article Category:
Research Article
Print Publication Date:
01 May 2019
Online Publication Date:
May 2019

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 6474 664 61
PDF Downloads 3078 305 17
EPUB Downloads 0 0 0